Lin Fang

Toulouse School of Economics · Economics · 2026–27 job market

Fields

Finance, Macroeconomics

Job market paper

Biopharma firms trading below cash

While almost 100 U.S. biopharma firms went public during the pandemic stock market boom in 2020, half of them experienced scientific failure within a few years after the public offering and have traded below cash due to the scientific failure. The fact that firms are valued below their net cash suggests investors anticipate inefficient continuation and incomplete cash recovery after scientific failure. Motivated by this evidence, I develop and estimate a biopharma start-up financing model to study whether it is rational to provide clinical-stage biopharma firms with so much funding upfront. The optimal contract trades off the cost of inefficient continuation under upfront financing against the dilution cost of follow-on equity issuance with staged capital injections. The model shows that upfront financing is optimal for late-clinical-stage projects, but it cannot fully explain the observed upfront financing for early-clinical-stage projects. In addition, estimated project characteristics suggest that investors funded more innovative and riskier projects during the boom. These findings point to investors' preference for innovative projects in hot markets, as well as potential speculative motives, as explanations for the upfront financing.